KALA KALA BIO Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Brazzell Romulus K	2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [ KALA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Medical Officer
(Last)          (First)          (Middle) C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 210	3. Date of Earliest Transaction (MM/DD/YYYY) 4/9/2020
(Street) WATERTOWN, MA 02472 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	4/9/2020		M		1880	A	$0.68	110605	D
Common Stock	4/9/2020		M		18247	A	$2.30	128852	D
Common Stock	4/9/2020		M		47644	A	$3.34	176496	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.68	4/9/2020		M			1880	(1)	5/9/2023	Common Stock	1880	$0.00	0	D
Stock Option (right to buy)	$2.30	4/9/2020		M			18247	(2)	10/1/2021	Common Stock	18247	$0.00	0	D
Stock Option (right to buy)	$3.34	4/9/2020		M			47644	(3)	6/16/2026	Common Stock	47677	$0.00	13508	D

Explanation of Responses:
(1)	The option became fully vested on December 31, 2017.
(2)	The option became fully vested on September 25, 2018.
(3)	This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on June 17, 2017 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Brazzell Romulus K C/O KALA PHARMACEUTICALS, INC. 490 ARSENAL WAY, SUITE 210 WATERTOWN, MA 02472			Chief Medical Officer

Signatures
/s/ Eric Trachtenberg, Attorney-in-Fact		4/13/2020
**Signature of Reporting Person		Date